
Opinion|Videos|August 14, 2024
Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy
Medical experts examine strategies for monitoring treatment response in patients initiating first-line immune checkpoint inhibitor-based therapy for metastatic renal cell carcinoma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
NCCN Guidelines in nccRCC Weigh New Data for Combinations
3
CARTITUDE-4: Cilta-Cel May Offer Curative Potential in Standard-Risk R/R Myeloma
4
Microbiota-Based MaaT013 Shows Strong Efficacy in Refractory GI-aGVHD
5







































